Straits Times Index
3,144.76 -38.85 (-1.22%) S&P 500
5,059.66 -2.16 (-0.04%) Dow
37,847.48 +112.37 (+0.30%) Nasdaq
15,890.90 +5.88 (+0.04%) Bitcoin USD
62,862.88 -462.20 (-0.73%) CMC Crypto 200
885.54 0.00 (0.00%)
Amarin Corporation plc (AMRN)
| Previous close | 0.9186 |
| Open | 0.9200 |
| Bid | 0.8586 x 100 |
| Ask | 0.9009 x 100 |
| Day's range | 0.8900 - 0.9401 |
| 52-week range | 0.6500 - 1.4900 |
| Volume | |
| Avg. volume | 1,778,135 |
| Market cap | 359.855M |
| Beta (5Y monthly) | 2.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1500 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.08 |
GlobeNewswireAmarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
DUBLIN, Ireland and BRIDGEWATER, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss its first quarter 2024 results followed by Q&A on Wednesday, May 1st, 2024, at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s first quarter 2024 financial results in the pre-market hours. To enhance
- GlobeNewswire
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of ActionDUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted three data presentations at ACC.24 showcasing the mechanistic activity of Eicosapentaenoic acid (EPA), including the potential effects of EPA on endothelial cell dysfunction and on oxidation of samples enriched with Lp(a). ”The data presented at ACC.24 provide new evidence surrounding
CNW GroupNew REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, today highlighted two data presentations at the 73rd Annual Scientific Sessions of the American College of Cardiology (ACC.24) describing the effects of VASCEPA (icosapent ethyl) on reducing Major Adverse Cardiovascular Events (MACE) in patients with baseline high or low Lipoprotein(a) [Lp(a)] levels, as well as r
